Lv61
2940 积分 2021-12-01 加入
Sotorasib (960 mg or 240 mg) once daily in patients with previously treated KRAS G12C-mutated advanced NSCLC
1个月前
已完结
[Guidelines on clinical practice of molecular tests in non-small cell lung cancer in China (2024 version)]
3个月前
已完结
[Expert consensus on clinical practice of fusion genes detection in non-small cell lung cancer in China (2023 version)]
3个月前
已完结
Overdiagnosis of Lung Cancer due to Introduction of Low-Dose Computed Tomography in Average-Risk Populations in China
3个月前
已完结
ALK-positive lung cancer: a moving target
6个月前
已完结
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
6个月前
已完结
Lazertinib in EGFR-Variant Non–Small Cell Lung Cancer With CNS Failure to Prior EGFR Tyrosine Kinase Inhibitors
9个月前
已完结
The Role of Lazertinib in Patients With EGFR-Variant Non–Small Cell Lung Cancer
9个月前
已完结
Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis
9个月前
已完结
Impact of PD-L1 expression on the efficacy of first-line crizotinib in advanced ROS1-rearranged NSCLC
10个月前
已完结
皖公网安备34019202002308
